Maceler Aldrovandi
- Molecular Biology
- Pulmonary and Respiratory Medicine top 10%
- Cancer Research top 10%
- Biochemistry top 5%
- Immunology
- Co-authors
- Valerie B. O’DonnellRobert C. MurphyMarcus ConradDavid A. SlatterGerhard KrönkeEikan MishimaBettina PronethAndré Mourão
- Topics
- Sphingolipid Metabolism and Signaling (6 papers)Eicosanoids and Hypertension Pharmacology (4 papers)Ferroptosis and cancer prognosis (3 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Maceler Aldrovandi
18 papers receiving 751 citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Molecular Biology 486
- Pulmonary and Respiratory Medicine 239
- Cancer Research 188
- Biochemistry 102
- Immunology 99
Countries citing papers authored by Maceler Aldrovandi
This map shows the geographic impact of Maceler Aldrovandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maceler Aldrovandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maceler Aldrovandi more than expected).
Fields of papers citing papers by Maceler Aldrovandi
This network shows the impact of papers produced by Maceler Aldrovandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maceler Aldrovandi. The network helps show where Maceler Aldrovandi may publish in the future.
Co-authorship network of co-authors of Maceler Aldrovandi
This figure shows the co-authorship network connecting the top 25 collaborators of Maceler Aldrovandi. A scholar is included among the top collaborators of Maceler Aldrovandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maceler Aldrovandi. Maceler Aldrovandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | Phase separation of FSP1 promotes ferroptosisbreakdown → | 228 |
| 3 | 5 | |
| 4 | 33 | |
| 5 | 5 | |
| 6 | 26 | |
| 7 | 76 | |
| 8 | 3 | |
| 9 | 36 | |
| 10 | 25 | |
| 11 | 13 | |
| 12 | 14 | |
| 13 | 132 | |
| 14 | 33 | |
| 15 | 10 | |
| 16 | 40 | |
| 17 | 22 | |
| 18 | 61 |
About Maceler Aldrovandi
Maceler Aldrovandi is a scholar working on Biochemistry, Clinical Biochemistry and Cancer Research, having authored 18 papers that have together received 764 indexed citations. Recurring topics across this work include Sphingolipid Metabolism and Signaling (6 papers), Eicosanoids and Hypertension Pharmacology (4 papers) and Ferroptosis and cancer prognosis (3 papers). The work is most often cited by research in Biochemistry (102 citations), Cancer Research (188 citations) and Pulmonary and Respiratory Medicine (239 citations). Maceler Aldrovandi has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Valerie B. O’Donnell, Robert C. Murphy, Marcus Conrad, David A. Slatter, Gerhard Krönke, Eikan Mishima, Bettina Proneth, André Mourão, Michael Sattler and Jan Borggräfe. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.